SHORT COMMUNICATION

Determination of antimicotic susceptibility pattern of *Candida* species isolated from patients with symptomatic candiduria

Mitra Barati[1,2], Shiva Mirkalantari[3,4], Saham Ansari[5], Samira Salari[6,7], Azam Fattahi[8]

[1]Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran, [2]Department of Infectious Disease, Rasul-e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran, [3]Department of Microbiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran, [4]Microbiol Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran, [5]Department of Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran, [6]Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran, [7]Department of Medical Mycology and Parasitology, School of Medicine, Medical University of Kerman, Kerman, Iran, [8]Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences, Tehran, Iran

Background: The present study was conducted to determine antimicotic susceptibility of *Candida* species (sp.) from patients with symptomatic candiduria. **Materials and Methods:** Identification of *Candida* sp. and determination of efficacy of most routine antifungals were done using polymerase chain reaction-restriction fragment length polymorphism method and E-test, respectively. **Results:** The results from susceptibility test reveal that caspofungin and amphotericin B have high antifungal activity against both albicans (100% and 96%, respectively) and nonalbicans (95.11% and 72.72%, respectively) isolates. **Conclusion:** The present study suggests that caspofungin and amphotericin B have the excellent ability to eradicate both *Candida* groups that showed decreased susceptibility to other compounds.

Keywords: Antifungal drugs, *Candida* species, polymerase chain reaction-restriction fragment length polymorphism, symptomatic candiduria

How to cite this article: Barati M, Mirkalantari S, Ansari S, Salari S, Fattahi A. Determination of antimicotic susceptibility pattern of *Candida* species isolated from patients with symptomatic candiduria. J Res Med Sci 2019;24:35.

INTRODUCTION

Candiduria has been considered as a challenging condition for clinicians because of the complex relationship between its colonization and infection. The complication occurs during long-term hospitalization, especially in individuals who are admitted in the intensive care unit setting that may lead to changes in etiologic agent to nonalbicans *Candida* (NAC).[1] This pictorial variation has created a new and serious complication because a broad spectrum of NAC isolates are typically less susceptible to routine antimicotic.[2] Clinically, amphotericin B and fluconazole were prescribed as the superior choice for the treatment of candiduria.[3] On the other side, a serious concern remains due to the intrinsic resistance of *Candida glabrata* and *Candida krusei* isolates to fluconazole.[4]

In the present study, we aimed to determine the *in vitro* antifungal susceptibility profile of *Candida* sp. from patients with symptomatic candiduria against amphotericin B, fluconazole, itraconazole, voriconazole, and caspofungin.

MATERIALS AND METHODS

Subjects

The experimental study was conducted in 2017. The patients who were suspected of sepsis, candiduria,

Access this article online

Quick Response Code:

Website: www.jmsjournal.net

DOI: 10.4103/jrms.JRMS_880_18

Address for correspondence: Dr. Azam Fattahi, Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences, Tehran, Iran. E-mail: afattahi@sina.tums.ac.ir

Received: 17-11-2018; **Revised:** 01-01-2019; **Accepted:** 16-01-2019

and the presence of pyuria were enrolled for this study. Therefore, 500 midstream of first-void urine and indwelling urinary catheter were collected.

Identification of *Candida* sp.

Identification of *Candida* sp. was performed based on direct examination, colony color, and yeast counts superior to 10^5 UFC/mL on CHROM Agar *Candida* medium (CHROM agar, France) at 35°C for 24 h.

The polymerase chain reaction-restriction fragment length polymorphism (RFLP) was performed based on the amplification of ITS1-5.8SrDNA-ITS2 region and *MspI* (Fermentas, USA) restriction enzyme. Restriction fragments were separated by 2% agarose gel electrophoresis.

Antimicotic susceptibility assay

The susceptibility of amphotericin B, fluconazole, itraconazole, voriconazole, and caspofungin was performed using RPMI 1640 agar-based E-test method (BioMeriéux, Sweden).[5] *Candida albicans* ATCC 24433 was used as the reference control.

RESULTS

Totally, 89 (17.8%) urine samples were positive for *Candida* species which collected from 43 (48.3%) male and 46 (51.6%) female individuals were positive for symptomatic candiduria. The mean age of participants in this study was 57.66 ± 22.30. Fever experience was recorded in 70.8% of patients while other clinical manifestations such as abdominal pain, renal pain, and dysuria were observed in 12.4%, 5.6%, and 6.7% of cases, respectively.

RFLP fingerprint analysis revealed that *C. albicans* (*n* = 56; 63%) is the predominant causative agent isolated from urine followed by *Candida tropicalis* (*n* = 24; 27%), *Candida parapsilosis* (5; 5.6%), *C. glabrata* (*n* = 2; 2.2%), and *C. krusei* (*n* = 2; 2.2%) [Figure 1].

The results from antimycotic susceptibility tests are presented in Table 1.



Figure 1: Polymerase chain reaction-restriction fragment length polymorphism fingerprint with MspI restriction enzyme: *Candida* albicans: 80, 40, 46, 47, 17; *Candida* tropicalis: 38, 39, 19, 18, 13, 14, 15; *Candida* parapsilosis: 3; *Candida* krusei: 16

Table 1: A head-to-head comparison of five antifungal susceptibilities profile in *Candida* sp.

Species (*n*)	Antifungals	E-test		
		S	I	R
Candida albicans (56)	AMB	96	0	4
	VCZ	92	8	0
	ICZ	77.82	16	6.8
	FCZ	90	10	0
	CAS	100	0	0
Candida tropicalis (24)	AMB	83.33	16.66	8.33
	VCZ	70.80	20	9.2
	ICZ	66.6	68.33	16.66
	FCZ	75	25	8.33
	CAS	95.11	0	5.89
Candida parapsilosis (5)	AMB	90	8	2
	VCZ	60	40	0
	ICZ	40	0	0
	FCZ	40	60	0
	CAS	100	0	0
Candida krusei (2)	AMB	100	0	0
	VCZ	100	0	0
	ICZ	0	100	0
	FCZ	0	60	40
	CAS	100	0	0
Candida glabrata (2)	AMB	100	0	0
	VCZ	100	0	0
	ICZ	0	50	50
	FCZ	0	0	100
	CAS	100	0	0

AMB=Amphotericin B; FCZ=Fluconazole; ICZ=Itraconazole; VCZ=Voriconazole; CAS=Caspofungin; S=Susceptible; I=Intermediate; R=Resistance

DISCUSSION

In line with previous studies regardless of asymptomatic and symptomatic candiduria,[6-8] the current results based on RFLP pattern revealed that *C. albicans* (63%) is still the predominant causative agent isolated from urine followed by *C. tropicalis* (27%), *C. parapsilosis* (5.6%), *C. glabrata,* and *C. krusei* (2.2%).

An overall look through the results from susceptibility test reveals that caspofungin and amphotericin B have high antimicotic activity against both albicans (100%–96%, respectively) and non albicans (95.11% and 72.72%, respectively) isolates. In line with other investigations,[8-11] the present finding suggests that caspofungin and amphotericin B are suitable alternatives in all cases of *Candida* sp. that showed resistance to azolic compounds.

It has been well established that *C. albicans* is intrinsically sensitive to a broad range of antimicotic classes and resistance must be acquired.[8-10] In concordance with this finding, results in this study show that *C. albicans* is largely susceptible to all antimicotic agents that were used here

except itraconazole. In practice, itraconazole is normally more effective than fluconazole, and it should be prescribed for cases with fluconazole-resistant isolates. Here, emerging resistant isolates were probably associated with previous exposure to fluconazole.

Regarding susceptibility results, decreased susceptibility to voriconazole was exclusively limited to *C. tropicalis*. In several studies, voriconazole-resistant *C. tropicalis* were clinically isolated.[12] In contrast with the present findings, recent investigations in candiuria indicated that no resistance was found among *C. tropicalis*.[8,10]

The rate of resistance to itraconazole varies between NAC isolates; here, the highest rate of resistance to itraconazole was found in *C. tropicalis and C. parapsilosis* species. The resistance to itraconazole has been reported in *C. tropicalis* and *C. glabrata* isolated from urine specimen.[1]

Similar to previous findings in the current investigation, *C. glabrata* and *C. krusei* showed the decreased sensitivity against fluconazole.[1,8] Interestingly, the high fluconazole resistance was determined for *C. tropicalis* and *C. parapsilosis*. Decreased fluconazole sensitivity to *C. tropicalis* was reported.[1,8,10,13] Since, multiple treatment guidelines recommend fluconazole as a first-line antifungal for candiduria emerging resistance to fluconazole in NAC has complicated treatment and is a warning for clinicians and public health authorities.

Finally, the present study suggests that caspofungin and amphotericin B have the excellent ability to eradicate both *Candida* groups that showed decreased susceptibility to other compounds. Taken together, widespread use of antimicotic, emerging new pathogens in addition to misidentification of fungal agents, may lead to poorer clinical outcomes and difficulty of treatment and is an alarm for clinician and public health authorities.

Acknowledgments

This research has been financially supported by Iran University of Medical Sciences grant No: 25619.

Financial support and sponsorship

This research has been financially supported by Iran University of Medical Sciences grant No: 25619.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Singla N, Gulati N, Kaistha N, Chander J. *Candida* colonization in urine samples of ICU patients: Determination of etiology, antifungal susceptibility testing and evaluation of associated risk factors. Mycopathologia 2012;174:149-55.
2. Bicmen C, Doluca M, Gulat S, Gunduz AT, Tuksavul F. Species level identification and antifungal susceptibility of yeasts isolated from various clinical specimens and evaluation of integral system yeasts plus. New Microbiol 2012;35:327-34.
3. Voltan AR, Fusco-Almeida AM, Mendes-Giannini MJ. Candiduria: epidemiology, resistance, classical and alternative antifungals drugs. SOJ Microbiol Infect Dis 2014;2:1-7.
4. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA, *et al.* Antifungal susceptibilities of *Candida* species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005;43:2155-62.
5. Zareifar S, Badiee P, Haddadi P, Abdolkarimi B. Susceptibility pattern of anti-candida drugs in the pediatric patients with acute leukemia. Iran J Ped Hematol Oncol 2017;7:1-8.
6. Esmailzadeh A, Zarrinfar H, Fata A, Sen T. High prevalence of candiduria due to non-albicans *Candida* species among diabetic patients: A matter of concern? J Clin Lab Anal 2018;32:e22343.
7. Zarei-Mahmoudabadi A, Zarrin M, Ghanatir F, Vazirianzadeh B. Candiduria in hospitalized patients in teaching hospitals of Ahvaz. Iran J Microbiol 2012;4:198-203.
8. Toner L, Papa N, Aliyu SH, Dev H, Lawrentschuk N, Al-Hayek S. Candida growth in urine cultures: a contemporary analysis of species and antifungal susceptibility profiles. QJM: Int J Med 2015;109: 325-9.
9. Zarei Mahmoudabadi A, Rezaei-Matehkolaei A, Ghanavati F. The susceptibility patterns of *Candida* species isolated from urine samples to posaconazole and caspofungin. Jundishapur J Microbiol 2015;8:e24298.
10. de Freitas AR, Baeza LC, Faria MG, Dota KF, Godoy Martínez P, Svidzinski TI, *et al.* Yeasts isolated from nosocomial urinary infections: Antifungal susceptibility and biofilm production. Rev Iberoam Micol 2014;31:104-8.
11. Zarei-Mahmoudabadi A, Zarrin M, Beheshti Fard M. Antifungal susceptibility of *Candida* species isolated from candidura. Jundishapur J Microbiol 2013;6:24-8.
12. Fothergill AW, Sutton DA, McCarthy DI, Wiederhold NP. Impact of new antifungal breakpoints on antifungal resistance in *Candida* species. J Clin Microbiol 2014;52:994-7.
13. Seifi Z, Azish M, Salehi Z, Zarei Mahmoudabadi A, Shamsizadeh A. Candiduria in children and susceptibility patterns of recovered *Candida* species to antifungal drugs in Ahvaz. J Nephropathol 2013;2:122-8.